AptarGroup 과거 순이익 실적
과거 기준 점검 3/6
AptarGroup은 연평균 13.2%의 비율로 수입이 증가해 온 반면, Packaging 산업은 수입이 1.7% 감소했습니다. 매출은 연평균 4%의 비율로 증가했습니다. AptarGroup의 자기자본이익률은 14.5%이고 순이익률은 10%입니다.
핵심 정보
13.18%
순이익 성장률
12.93%
주당순이익(EPS) 성장률
| Packaging 산업 성장률 | 12.01% |
| 매출 성장률 | 4.03% |
| 자기자본이익률 | 14.46% |
| 순이익률 | 9.98% |
| 다음 순이익 업데이트 | 30 Jul 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
내러티브 업데이트 • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.내러티브 업데이트 • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).내러티브 업데이트 • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
내러티브 업데이트 • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.내러티브 업데이트 • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
내러티브 업데이트 • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.내러티브 업데이트 • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.분석 기사 • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...내러티브 업데이트 • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.내러티브 업데이트 • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).내러티브 업데이트 • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Seeking Alpha • Nov 02
AptarGroup: Pharma Setback Creates Long-Term Opportunities
Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking Alpha내러티브 업데이트 • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.분석 기사 • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...내러티브 업데이트 • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.분석 기사 • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...분석 기사 • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...분석 기사 • Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?
Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • May 13
AptarGroup's (NYSE:ATR) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
새 내러티브 • Aug 25
Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge
Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.매출 및 비용 세부 내역
매출 및 비용 세부 내역
AptarGroup가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 3,873 | 387 | 614 | 0 |
| 31 Dec 25 | 3,777 | 393 | 601 | 0 |
| 30 Sep 25 | 3,663 | 419 | 583 | 0 |
| 30 Jun 25 | 3,611 | 392 | 582 | 0 |
| 31 Mar 25 | 3,555 | 370 | 581 | 0 |
| 31 Dec 24 | 3,583 | 375 | 578 | 0 |
| 30 Sep 24 | 3,573 | 336 | 581 | 0 |
| 30 Jun 24 | 3,557 | 320 | 577 | 0 |
| 31 Mar 24 | 3,543 | 313 | 569 | 0 |
| 31 Dec 23 | 3,487 | 284 | 564 | 0 |
| 30 Sep 23 | 3,445 | 281 | 561 | 0 |
| 30 Jun 23 | 3,389 | 251 | 559 | 0 |
| 31 Mar 23 | 3,337 | 232 | 554 | 0 |
| 31 Dec 22 | 3,322 | 239 | 554 | 0 |
| 30 Sep 22 | 3,340 | 238 | 561 | 0 |
| 30 Jun 22 | 3,329 | 231 | 560 | 0 |
| 31 Mar 22 | 3,295 | 223 | 562 | 0 |
| 31 Dec 21 | 3,227 | 244 | 553 | 0 |
| 30 Sep 21 | 3,163 | 240 | 536 | 0 |
| 30 Jun 21 | 3,096 | 256 | 519 | 0 |
| 31 Mar 21 | 2,985 | 243 | 500 | 0 |
| 31 Dec 20 | 2,929 | 214 | 497 | 0 |
| 30 Sep 20 | 2,851 | 209 | 469 | 0 |
| 30 Jun 20 | 2,793 | 202 | 462 | 0 |
| 31 Mar 20 | 2,837 | 234 | 456 | 0 |
| 31 Dec 19 | 2,860 | 242 | 453 | 0 |
| 30 Sep 19 | 2,873 | 234 | 441 | 0 |
| 30 Jun 19 | 2,838 | 217 | 434 | 0 |
| 31 Mar 19 | 2,806 | 198 | 428 | 0 |
| 31 Dec 18 | 2,765 | 195 | 430 | 0 |
| 30 Sep 18 | 2,706 | 204 | 420 | 0 |
| 30 Jun 18 | 2,664 | 218 | 412 | 0 |
| 31 Mar 18 | 2,571 | 228 | 401 | 0 |
| 31 Dec 17 | 2,469 | 220 | 387 | 0 |
| 30 Sep 17 | 2,382 | 220 | 375 | 0 |
| 30 Jun 17 | 2,348 | 220 | 366 | 0 |
| 31 Mar 17 | 2,350 | 214 | 366 | 0 |
| 31 Dec 16 | 2,331 | 206 | 364 | 0 |
| 30 Sep 16 | 2,339 | 199 | 363 | 0 |
| 30 Jun 16 | 2,335 | 200 | 358 | 0 |
| 31 Mar 16 | 2,310 | 198 | 351 | 0 |
| 31 Dec 15 | 2,317 | 199 | 351 | 0 |
| 30 Sep 15 | 2,370 | 198 | 356 | 0 |
| 30 Jun 15 | 2,435 | 193 | 366 | 0 |
양질의 수익: ATR는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: ATR의 현재 순 이익률 (10%)은 지난해 (10.4%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: ATR의 수익은 지난 5년 동안 연평균 13.2% 증가했습니다.
성장 가속화: 지난 1년간 ATR 의 수익 증가율(4.4%)은 5년 평균(연간 13.2%)보다 낮습니다.
수익 대 산업: ATR의 지난 1년 수익 증가율(4.4%)은 Packaging 업계의 -1.7%를 상회했습니다.
자기자본이익률
높은 ROE: ATR의 자본 수익률(14.5%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/06 09:45 |
| 종가 | 2026/05/06 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AptarGroup, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |